中国药物警戒 ›› 2018, Vol. 15 ›› Issue (11): 690-692.

• 安全性评价与合理用药 • 上一篇    下一篇

硫酸羟氯喹片致QT间期延长综合征1例的药学监护

赵瑞, 崔向丽, 刘丽宏*   

  1. 首都医科大学附属北京朝阳医院药事部,北京 100020
  • 收稿日期:2018-03-09 修回日期:2019-01-09 出版日期:2018-11-20 发布日期:2019-01-09
  • 通讯作者: 刘丽宏,女,博士,主任药师·博导,医院药学。
  • 作者简介:赵瑞,女,博士,主管药师,临床药学。

Pharmaceutical Care of a Patient with Hydroxychloroquine Induced Long QT Syndrome

ZHAO Rui, CUI Xiangli, LIU Lihong*   

  1. Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China
  • Received:2018-03-09 Revised:2019-01-09 Online:2018-11-20 Published:2019-01-09

PDF (PC)

225

摘要： 目的 分析1例硫酸羟氯喹片引起的QT间期延长不良反应的药学监护,为临床安全用药提供参考。方法 通过分析患者治疗过程中出现室颤与治疗药物的相关性,检索相关文献,寻找治疗过程中引起QT间期延长的药物。结果 该例患者出现QT间期延长继而发生室颤,确系因服用硫酸羟氯喹片用药相关。结论 确定了一例硫酸羟氯喹片新报道的不良反应,提示临床需重视该药对心脏的毒性并加强用药后监护。

关键词: 羟氯喹, 药品不良反应, 长QT间期综合征

Abstract: Objective To analyze pharmaceutical care on one case of long QT syndrome(LQTS) induced by hydroxychloroquine (HCQ) sulfate tablets, so as to provide reference to the clinical safe medication. Methods By collecting the correlative papers and analyzing clinical drug use, we analyzed the correlation between the prescriptions and LQTS. Results HCQ has a significant correlation with LQTS, it induced prolongation of the QT interval and torsades de pointes(TdP). Conclusion HCQ is a drug with conditional TdP risk. We should pay attention to clinical medication and measures to prevent and deal with similar ADR.

Key words: hydroxychloroquine(HCQ), adverse drug reaction(ADR), long QT syndrome

中图分类号: